For research use only. Not for therapeutic Use.
Luxdegalutamide（Cat No.:I041294）is an investigational oral androgen receptor antagonist being developed for the treatment of prostate cancer, particularly metastatic castration-resistant prostate cancer (mCRPC). It works by binding to the androgen receptor, preventing androgen hormones like testosterone from activating the receptor, which is crucial for the growth and survival of prostate cancer cells. Luxdegalutamide has shown promising preclinical and early clinical trial results in reducing tumor progression and enhancing patient outcomes. This novel compound offers a targeted approach, aiming to improve efficacy and reduce side effects compared to existing therapies for prostate cancer.
| CAS Number | 2750830-09-0 |
| Synonyms | 4-[4-[[1-[4-[[3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-N-[(3S)-2,6-dioxopiperidin-3-yl]-2-fluorobenzamide |
| Molecular Formula | C45H54FN7O6 |
| Purity | ≥95% |
| IUPAC Name | 4-[4-[[1-[4-[[3-(4-cyano-3-methoxyphenoxy)-2,2,4,4-tetramethylcyclobutyl]carbamoyl]phenyl]piperidin-4-yl]methyl]piperazin-1-yl]-N-[(3S)-2,6-dioxopiperidin-3-yl]-2-fluorobenzamide |
| InChI | InChI=1S/C45H54FN7O6/c1-44(2)42(45(3,4)43(44)59-33-12-8-30(26-47)37(25-33)58-5)50-39(55)29-6-9-31(10-7-29)52-18-16-28(17-19-52)27-51-20-22-53(23-21-51)32-11-13-34(35(46)24-32)40(56)48-36-14-15-38(54)49-41(36)57/h6-13,24-25,28,36,42-43H,14-23,27H2,1-5H3,(H,48,56)(H,50,55)(H,49,54,57)/t36-,42?,43?/m0/s1 |
| InChIKey | RDPPBRKNBBXPNZ-PJXMSJPKSA-N |
| SMILES | CC1(C(C(C1OC2=CC(=C(C=C2)C#N)OC)(C)C)NC(=O)C3=CC=C(C=C3)N4CCC(CC4)CN5CCN(CC5)C6=CC(=C(C=C6)C(=O)N[C@H]7CCC(=O)NC7=O)F)C |
| Chemistry Calculators | Dilution Calculator In vivo Formulation Calculator Molarity Calculator Molecular Weight Calculator Reconstitution Calculator |
